Decoy Therapeutics Inc. (DCOY)
$0.00+$0.00 (+0.00%) Latest sessionExtended Hours
Latest DCOY Insider Trades
Arnold C. Hanish - DirectorOpen-market purchase$4K
Arnold C. Hanish - Director
Jonathan I. Lieber - DirectorArnold C. Hanish - DirectorDecoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 10 | 65,253 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
12 Form 4 filings on record, the earliest from Nov 20, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jonathan I. Lieber - Director | Grant or award | Common Stock | 2,000 | $0.00 | - | |
| Frederick Pierce II - Officer | Grant or award | Common Stock | 33,455 | $0.00 | - | |
| Peter Klaus Marschel - Officer | Grant or award | Common Stock | 3,900 | $0.00 | - | |
| Mark J. Rosenblum - Officer | Grant or award | Common Stock | 9,682 | $0.00 | - | |
| Barbara Louise Hibner - Officer | Grant or award | Common Stock | 4,216 | $0.00 | - | |
| Arnold C. Hanish - Director | Grant or award | Common Stock | 3,000 | $0.00 | - | |
| Paul Lammers - Director | Grant or award | Common Stock | 2,000 | $0.00 | - | |
| Tess Burleson - Director | Grant or award | Common Stock | 2,000 | $0.00 | - | |
| William K. McVicar - Director | Grant or award | Common Stock | 3,000 | $0.00 | - | |
| Patricia G. Gauthier - Director | Grant or award | Common Stock | 2,000 | $0.00 | - | |
| Arnold C. Hanish - Director | Open-market purchase | Common Stock | 5,000 | $8.98 | $4K | |
| Mark J. Rosenblum - Officer | Open-market purchase | Common Stock | 20,000 | $9.60 | $16K |
Decoy Therapeutics Inc. (DCOY) had 10 insider filings in the last 90 days, with the most recent on 2026-09-02. The full record for DCOY runs to 12 Form 4 filings, the earliest from 2025-11-20. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of DCOY were filed in the last 90 days. 2 purchases are on record for this company.
No insider sales of DCOY were filed in the last 90 days.
This page tracks DCOY Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add DCOY to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
